Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor & Ectodomain Shedding Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADAM9 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADAM9 ECD-Fc / Mutant Protein (HEK293, >95%, Endotoxin <1 EU/µg, Sequence Verified) | View ADAM9 Products |
| Gene Delivery | ADAM9 Promise-ORF / Lentivirus Particles (Full-length ORF for stable cell line engineering) | View ADAM9 Products |
| Reference Antibody | Anti-ADAM9 Recombinant (Sequence of IMGC936) – Chimeric positive control for binding & internalization | View ADAM9 Products |
| Validator | ADAM9 siRNA Set (3 unique targets) – Knockdown verification for specificity controls | View ADAM9 Products |
| Off-Target Homolog 1 | ADAM17 (TACE) ECD Protein – Counter-screening for ADAM subfamily selectivity | View ADAM17 Products |
| Off-Target Homolog 2 | ADAM10 ECD Protein – Additional homolog for selectivity panel | View ADAM10 Products |
| Pathway Partner | EGFR / HER1 ECD Protein – Downstream signaling node for sheddase pathway studies | View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADAM Subfamily Selectivity (ADAM17/10/12 cross-reactivity) | Human ADAM9, ADAM17, ADAM10, ADAM12 ortholog ECD proteins; >95% purity, Sequence Verified by Mass Spec for strict epitope discrimination. |
| Cross-species Cyno/Mouse Evaluation | Human / Cynomolgus / Mouse ADAM9 ECD-Fc proteins with matched HEK293 expression for consistent glycosylation and immunogenicity prediction. |
| Internalization & Trafficking Validation | High-purity ADAM9 ECD-Fc for binding confirmation; lentivirus full-length stable cell lines preserve native conformation for pH-sensitive dye & flow cytometry. |
| Assay Specificity & False Positives | ADAM9-targeted siRNA set included for genetic knockdown confirmation; eliminates artifacts from non-specific antibody binding. |
Live ADAM9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADAM9 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum metalloprotease inhibitors to highly targeted biologics. First-generation small-molecule MMP/ADAM inhibitors suffered from dose-limiting toxicities due to poor selectivity. The current wave of R&D centers on ADAM9 as a tumor-associated antigen for Antibody-Drug Conjugates (ADCs), leveraging its elevated expression in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), gastric cancer, and other solid tumors. The leading program, IMGC936 (ImmunoGen/MacroGenics), demonstrates the ADC approach targeting ADAM9 with a cleavable linker and DM4 payload. Other modalities include bispecific antibodies, anti-sheddase monoclonal antibodies, and selective small-molecule inhibitors. As these programs advance, the next frontier will focus on combination strategies with checkpoint inhibitors and EGFR-targeted therapies, alongside rigorous counter-screening against the highly homologous ADAM17 (TACE) to ensure a favorable therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | ImmunoGen, MacroGenics; early-stage biotechs | PDAC, NSCLC, TNBC, Gastric | Internalization Assay (high-purity ECD-Fc & stable full-length cell lines) |
| Monoclonal Antibody (Anti-Sheddase) | OphthaliX, Bausch Health; biologics platforms | Solid Tumors, Neovascularization, Inflammation | Epitope Mapping & Subfamily Selectivity Panel (need ADAM10/17/12 homologs) |
| Bispecific Antibody | Immuno-oncology focused pipelines | Refractory Solid Tumors, EGFR-driven tumors | ADAM9/Effector Cell Engagement (need cross-species orthologs for preclinical evaluation) |
| Small Molecule Inhibitor | Structure-based drug design programs | Refractory Solid Tumors | Enzymatic Selectivity Assay (need ADAM9 catalytic domain vs WT/mutant paralogs) |
Structural & Functional Domains
ADAM9 (A Disintegrin And Metalloproteinase 9) is a type I transmembrane protein belonging to the ADAM family. It contains three key domains confirmed by UniProt (Q13443): a Peptidase M12B (metalloproteinase) domain responsible for ectodomain shedding of growth factors such as HB-EGF and amphiregulin; a Disintegrin domain mediating cell-cell and cell-matrix interactions; and an EGF-like domain that may contribute to receptor binding. These domains make ADAM9 a critical sheddase in the tumor microenvironment, constitutively activating the EGFR signaling pathway and driving proliferation, invasion, and drug resistance.
Target Identity & Validation
ADAM9 is the resolved target (UniProt Q13443, primary entry). The requested target and resolved target are identical, ensuring all reagents and references align precisely. No key mutations are documented in the current fact payload, indicating that wild-type reagents are suitable for most applications.